...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome - a pilot study -.
【24h】

Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome - a pilot study -.

机译：可溶性凝集素样氧化型低密度脂蛋白受体-1可预测急性冠脉综合征后的预后-一项先导研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is implicated in atherosclerotic plaque vulnerability. It is shed, in part, by proteases and released as soluble LOX-1 (sLOX-1), which is a specific and sensitive biomarker of acute coronary syndrome (ACS). The present study explored if sLOX-1 can also predict prognosis after ACS. METHODS AND RESULTS: ACS patients undergoing emergency percutaneous coronary intervention and measurement of circulating sLOX-1 were followed (median: 896 days). Among 94 patients, 13 had ACS recurrence or died (re-ACS/death group). None of age, sex, lipid profile or prevalence of diabetes, smoking or hypertension was significantly different between the re-ACS/death group and the event-free survival group. Circulating sLOX-1 levels, but not those of high-sensitivity C-reactive protein (hs-CRP) or troponin T (TnT), were significantly (P<0.005) higher in the re-ACS/death group than in the event-free survival group. Kaplan-Meier survival curves showed that ACS patients with sLOX-1 values in the highest quartile or tertile had more frequent and earlier ACS recurrence or death. Receiver-operating characteristic curves for prediction of re-ACS or death showed higher sensitivity and specificity for sLOX-1 (area under the curve for sLOX-1, hs-CRP and TnT: 0.764, 0.658 and 0.524, respectively). CONCLUSIONS: Circulating sLOX-1, a diagnostic biomarker of ACS, also predicts ACS recurrence or death.
机译：背景：凝集素样氧化的低密度脂蛋白受体1（LOX-1）与动脉粥样硬化斑块易损性有关。它部分地被蛋白酶释放，并以可溶性LOX-1（sLOX-1）的形式释放，这是急性冠状动脉综合征（ACS）的特异性和敏感生物标志物。本研究探讨了sLOX-1是否也可以预测ACS后的预后。方法和结果：ACS患者接受了急诊经皮冠状动脉介入治疗并测量了循环sLOX-1（中位数：896天）。在94例患者中，有13例ACS复发或死亡（re-ACS /死亡组）。再ACS /死亡组和无事件生存组之间的年龄，性别，血脂状况或糖尿病，吸烟或高血压的患病率均无显着差异。 re-ACS /死亡组的循环sLOX-1水平而非高敏C反应蛋白（hs-CRP）或肌钙蛋白T（TnT）的水平显着（P <0.005）高于事件-自由生存组。 Kaplan-Meier生存曲线显示，sLOX-1值在四分位数或三分位数最高的ACS患者发生ACS的频率更高，复发或死亡的时间也更早。预测re-ACS或死亡的受体操作特征曲线显示出对sLOX-1更高的敏感性和特异性（sLOX-1，hs-CRP和TnT曲线下的面积分别为0.764、0.658和0.524）。结论：循环sLOX-1，一种ACS的诊断性生物标志物，也可预测ACS的复发或死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号